FDA Approval Timeline for Retatrutide
Based on the available evidence, retatrutide has already received FDA approval in 2026 1. The drug label evidence confirms FDA approval status as of 2026.
Current Regulatory Status
The approval follows completion of the Phase III TRIUMPH clinical trial program, which demonstrated substantial efficacy and acceptable safety:
- TRIUMPH-2 (completed, published 2026): Enrolled 1,152 adults with obesity and type 2 diabetes across 92 centers in 8 countries 2
- TRIUMPH-1-OSA and TRIUMPH-2-OSA (completed, published 2026): Evaluated retatrutide specifically for obstructive sleep apnea in 243 and 448 participants respectively 3
The Phase III program began enrollment on July 11,2023, with TRIUMPH-2 completing by November 1,2024 2.
Clinical Evidence Supporting Approval
Weight Loss Efficacy:
- At 80 weeks, retatrutide achieved -18.8% mean weight loss with the 12 mg dose versus -5.1% with placebo (difference: -13.8%, 95% CI -15.8 to -11.8) in patients with obesity and type 2 diabetes 2
- Earlier Phase II data showed 24.2% weight loss at 48 weeks with 12 mg dosing 4
Glycemic Control:
- Participants had baseline HbA1c of 7.71% and demonstrated significant improvements in glycemic parameters 2
- 92% of participants were on oral glucose-lowering medications at baseline 2
Additional Indications: The approval appears to encompass multiple indications based on the TRIUMPH basket trial design, including obstructive sleep apnea where retatrutide reduced the apnea-hypopnea index by 21.9-24.4 events/hour compared to placebo 3.
Safety Profile
The most common adverse events were gastrointestinal (diarrhea in 27-34% vs 13% placebo; nausea in 14-28% vs 8% placebo), consistent with the GLP-1 receptor agonist class 2. Permanent discontinuation rates were 4-12% across dose groups, with higher rates at 9-12 mg doses 2.
Mechanism and Pharmacology
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors with a half-life of approximately 6 days supporting once-weekly subcutaneous dosing 5. This represents the first FDA-approved triple agonist for metabolic disease 6, 7.